Claims for Patent: 7,229,982

Summary for Patent: 7,229,982

Title:	Pharmaceutical formulation
Abstract:	The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.
Inventor(s):	Moore; William D. (Hoddesdon, Hertfordshire, GB), Fitzpatrick; Shaun (Hoddesdon, Hertfordshire, GB), Seiler; Christian (Hertford, GB), Saklatvala; Robert (Hoddesdon, Hertfordshire, GB), Petts; Catherine R. (Hoddesdon, Hertfordshire, GB)
Assignee:
Application Number:	10/625,004
Patent Claims:	1. A pharmaceutical composition comprised of from 1% to 20% by weight of ezetimibe; from 1% to 80% by weight of simvastatin; from 0.01% to 2% by weight of BHA; and from 0.1% to 1.25% by weight of citric acid, provided that the composition is not comprised of ascorbic acid. 2. The composition of claim 1 comprised of from 1.25% to 10% of ezetimibe, and from 1% to 20% of simvastatin. 3. The composition of claim 2 comprised of from 5% to 10% of simvastatin. 4. The composition of claim 1 comprised of 0.01% to 0.05% of BHA. 5. The composition of claim 4 comprised of about 0.02% of BHA. 6. The composition of claim 1 further comprised of 0.2% or less by weight of propyl gallate. 7. The composition of claim 6 comprised of from 0.001% to 0.05% by weight of propyl gallate. 8. The composition of claim 7 comprised of about 0.005% by weight of propyl gallate. 9. The composition of claim 1 further comprised of from 5% to 20% by weight of microcrystalline cellulose; from 1% to 4% by weight of hydroxypropyl methylcellulose; and from 0.5% to 2% by weight of magnesium stearate. 10. The composition of claim 1 further comprised of 10% or less by weight of croscarmellose sodium. 11. The composition of claim 10 comprised of from 2% to 4% by weight of croscarmellose sodium.. 12. The composition of claim 1 wherein the composition is a tablet and provided that the tablet does not have a film coating. 13. The composition of claim 1 provided that it is not comprised of pregelatinized starch. 14. An oral pharmaceutical composition comprised of from 5 mg to 20 mg of ezetimibe; from 5 mg to 80 mg of simvastatin; and from 0.002 mg to 0.004 mg of BHA per mg of simvastatin; wherein said composition further comprises from 0.1% to 1.25% by weight of citric acid, provided that the composition is not comprised of ascorbic acid. 15. The composition of claim 14 comprised of 10 mg of ezetimibe and a dosage amount of simvastatin selected from 5 mg, 10 mg, 20 mg, 40 mg and 80 mg. 16. The composition of claim 14 further comprised of 0.0005 mg to 0.001 mg of propyl gallate per mg of simvastatin. 17. The composition of claim 14 additionally comprised of from 1 mg to 640 mg of microcrystalline cellulose; from 0.5 mg to 80 mg of hydroxypropyl methylcellulose; from 0.1 mg to 32 mg of magnesium stearate; and lactose. 18. The composition of claim 17 comprised of from 15 mg to 120 mg of microcrystalline cellulose; from 2 mg to 16 mg of hydroxypropyl methylcellulose; and from 1.5 to 12 mg of magnesium stearate. 19. The composition of claim 14 further comprised of 80 mg or less of croscarmellose sodium. 20. The composition of claim 14 further comprised of 80 mg or less of citric acid. 21. A pharmaceutical composition consisting essentially of: 10.0 mg simvastatin; 10.0 mg ezetimibe; 15.0 mg microcrystalline cellulose; 58.23 mg lactose; 2.0 mg HPMC; 3.0 mg croscarmellose sodium; 0.25 mg citric acid; 0.005 mg propyl gallate; 0.02 mg BHA; and 1.5 mg magnesium stearate. 22. A pharmaceutical composition consisting essentially of: 20.0 mg of simvastatin; 10.0 mg of ezetimibe; 30.0 mg of microcrystalline cellulose; 126.45 mg of lactose; 4.0 mg of HPMC; 6.0 mg of croscarmellose sodium; 0.5 mg of citric acid; 0.01 mg of propyl gallate; 0.04 mg of BHA; and 3.0 mg of magnesium stearate. 23. A pharmaceutical composition consisting essentially of: 40.0 mg simvastatin; 10.0 mg ezetimibe; 60.0 mg microcrystalline cellulose; 262.90 mg lactose; 8.0 mg HPMC; 12.0 mg croscarmellose sodium; 1.0 mg citric acid; 0.02 mg propyl gallate; 0.08 mg BHA; and 6.0 mg magnesium stearate. 24. A pharmaceutical composition consisting essentially of: 80.0 mg simvastatin; 10.0 mg ezetimibe; 120.0 mg microcrystalline cellulose; 535.84 mg lactose; 16.0 mg HPMC; 24.0 mg croscarmellose sodium; 2.0 mg citric acid; 0.04 mg propyl gallate; 0.16mg BHA; and 12.0 mg magnesium stearate. 25. A method of treating one or more diseases associated with a vascular condition in a patient in need of such treatment by administering to the patient a therapeutically effective amount of a composition comprised of from 1% to 20% by weight of ezetimibe; from 1% to 80% by weight of simvastatin; from 0.0 1% to 2% by weight of BHA; and from 0.1% to 1.25% by weight of citric acid, provided that the composition is not comprised of ascorbic acid.